Objective To assess the clinical effectiveness and safety of laparoscopy versus laparotomy for endometrial cancer. Methods The databases such as The Cochrane Library, PubMed, EMbase, Ovid, CNKI, WanFang Data, and VIP were searched to collect the randomized control trials (RCTs) about the clinical effectiveness and safety of laparoscopy and laparotomy for endometrial cancer. The retrieval time was from January 1998 to September 2012. Two reviewers independently screened the literature according to the inclusive and exclusive criteria, extracted the data, and assessed the methodological quality of included studies. Then the meta-analysis was performed by using RevMan 5.0 software. Results A total of 10 RCTs involving 6 993 patients were included. Meta-analysis showed that, compared with laparotomy, laparoscopy had lesser amount of intraoperative bleeding, lower decrease of hemoglobin before and 1-day after operation, shorter time of both waiting for postoperative gas and hospital stay, lower incidence of postoperative complications, longer operation time, and higher incidence of intraoperative complications. Additionally, there were no differences between the 2 groups in the number of pelvic and para-aortic lymph nodes removed during operation, as well as the postoperative recurrence and mortality rates in 3-5 year follow-up. Conclusion Compared with laparotomy, laparoscopy shows lesser amount of intraoperative bleeding, lower decrease of hemoglobin before and 1-day after operation, shorter time of both waiting for postoperative gas and hospital stay, lower incidence of postoperative complications. But laparotomy shows lower incidences of intraoperative complications, and shorter operation time. Both operations are similar in the number of pelvic and para-aortic lymph nodes removed during operation, as well as the postoperative recurrence and mortality rates in 3-5 year follow-up. For quantity limitation and low methodological quality of included studies, this conclusion still needs to be further proved by performing more high-quality and large scale RCTs.
Objective To systematically evaluate the correlation between coffee and risk of endometrial cancer. Methods Such databases as CBM, CNKI, WanFang data, PubMed, EMbase and The Cochrane Library (Issue 5, 2012) were searched to collect the prospective cohort studies about correlation between coffee and endometrial cancer. The retrieval time was by the end of May 2012, and the references of the included literature were also retrieved. Two evaluators independently screened the literature according to the inclusion and exclusion criteria, extracted the data, and assessed the quality, and then the statistical analysis was conducted by using Stata 12.0 software. Results A total of 10 cohort studies involving 4 484 patients with endometrial cancer were included. The results of meta-analysis showed that, compared with the women who didn’t drink coffee or drank in the lowest dose, the women who drank coffee in the highest dose had a decreased risk of endometrial cancer (RR=0.69, 95%CI 0.62 to 0.78), same as the women who drank coffee frequently (RR=0.83, 95%CI 0.77 to 0.89). The results of dose-response analysis revealed that, when there was an increase of 2 more cups of coffee per day, there was the risk of endometrial cancer decreased by 12%. Conclusion Drinking coffee frequently (more than 2 cups per day) can decrease the risk of endometrial cancer which can be significantly decreased when drinking in a big dose (more than 5 cups per day).
Objective To assess the clinical effectiveness, safety and cost-effectiveness of adjuvant radiotherapy(RT) for endometrial cancer compared to other treatmen. Method The following electronic databases were searched: MEDLINE, EMBAS, CancerLit, CBMdisc, CNKI. The Cochrane Library (Issue 3, 2007). Correlative websites, such as ‘google’, were searched by hand. The studies included in the references of eligible studies were additionally searched RCTs of adjuvant radiotherapy before March, 2007 comparing adjuvant radiotherapy with other treatment for endometrial cancer were included. Eligible RCTs were assessed for quality by two reviewers independently: criteria of concealment of treatment, blinding, standard validity and reliability of outcome measures, withdraw rate, intention-to-treat analysis and homogeneity between centers were analyzed for each study. All data were performed by a meta-analysis. Result Seven RCTs met the inclusion criteria/ Methodological quality was level B. Five RCTs were compared adjuvant radiotherapy (external beam radiotherapy (EBRT) and /or intracavitary radiotherapy (ICRT) with other treatment, Two RCTs including one RCT was compared two different fractionation schedules for postoperative vagina high-dose-rate(HDR) irradiation in endometrial carcinoma the other RCT was compared two different radiotherapy method (pelvic radiotherapy and vagina radiotherapy vs vagina radiotherapy) for endometrial carcinoma. No survival different were identified; none of the studies was powered enough to show a survival benefit. But who received RT had fewer local (pelvic and/or vagina) recurrences compared to women not receiving RT. Adverse effects is found more often in RT than in not RT, there is less localrecurrences in combined radiotherapy (pelvic radiotherapy and vagina radiotherapy) than in vagina radiotherapy. lowdose vagina radiotherapy had few vagina shortening than high-dose radiotherapy, there are the same 5-overall surviva, local recurrences and distant recurrences. Conclusions Adjuvant radiotherapy for endometrial can cer can better control local recurrences than observation for postoperative endometrial cancer. Effects about overall survival, distant recurrences and disease-free survival are similar; low-dose vagina radiotherapy has few vagina shortening than high-dose radiotherapy, there are the same 5-years overall survival, local recurrences and distant recurrences for endometrial cancer, there is less local recurrences in combined radiotherapy (pelvic radiotherapy plus vagina radiotherapy) than in vagina radiotherapy for endometrial cancer; postoperative high-dose brachytherapy can get good cost-effectiveness; Effect of adjuvant radiotherapy for overall survival and disease-free survival of endometrial carcinoma are needed to further assessed by rigorously designs, randomized, double-blind, placebo-controlled trials adjuvant radiotherapy for endometrial carcinoma.
Objective To evaluate the clinical effectiveness, safety and cost-effectiveness of postoperative radiotherapy on endometrial carcinoma. Methods We searched The Cochrane Library, The Cochrane Central Register of Controlled Trials (CENTRAL), The National Research Register, Health Technology Assessment Database (HTA), MEDLINE, EMbase, CancerLit, CBMdisc, VIP, WANFANG DATABASE and CNKI to March 2007. Relevant journals were also hand searched. Study selection and assessment, data collection and analyses were undertaken by two reviewers independently according to the Cochrane Handbook for Systematic Reviews of Interventions. Meta-analyses were performed. Results Three RCTs involving 1126 patients were included. Each of the 3 RCTs compared adjuvant radiotherapy (external beam radiotherapy, EBRT) versus chemotherapy. Two trials (730 patients) compared adjuvant radiotherapy versus CAP chemotherapy (carboplatin + adriamycin + cisplatin). The other trial (396 patients) compared adjuvant radiotherapy versus AP chemotherapy (adriamycin + cisplatin). The meta-analyses showed that for patients with endometrial cancer at stage Ic, II or III, there were no significant differences between adjuvant radiotherapy and CAP in 5-year overall survival (OS), 5-year progress-free survival (PFS) and 5-year recurrence (local, distant, total). For patients with endometrial cancer at stage III or IV, adjuvant radiotherapy was superior to AP regimen on 5-year OS and 5-year PFS. The incidence of grade 3/4 toxicities of digestive system and urogenital system was similar between the two groups of patients. The chemotherapy group showed a higher incidence of grade 3/4 toxicities of hematology than the radiotherapy group. Conclusion The effect of adjuvant pelvic radiotherapy for endometrial carcinoma at stage Ic, II or III is similar to that of adjuvant chemotherapy. However, for endometrial carcinoma at stage III or IV, the effect of radiotherapy is superior to that of chemotherapy. Radiotherapy has a lower role of myelosuppression than chemotherapy. No significant difference was observed between the radiotherapy and chemotherapy in grade 3/4 toxicities of the digestive system and the urogenital system.
目的 探讨螺旋CT增强扫描在子宫内膜癌的表现和分期价值。 方法 2004年3月－2010年2月对40例子宫内膜癌术前均行CT平扫和增强扫描，并按世界妇产科联合会（FIGO）标准进行术前CT分期，且均经手术和病理证实。 结果 子宫内膜癌增强CT主要表现为：子宫前后径增大，子宫内膜增厚，宫腔扩大，其内可见强化程度低于子宫肌壁的乳头状、息肉状或不规则状软组织影，部份可见宫腔积液、积血或积脓；或子宫肌壁变薄、厚薄不均或不规则，宫颈增大、密度变低或不均；子宫外播散等相关表现。FIGO分期：Ⅰa期6例，Ⅰb期8例，Ⅰc期8例，Ⅱ期8例，Ⅲ期4例，Ⅳ期6例。其中2例Ⅰa期高估为Ⅰb期，3例Ⅱa期高估为Ⅱb期，2例Ⅱ期低估为Ⅰ期。Ⅰ、Ⅱ期CT分期准确率分别为81.82％、37.5%，Ⅲ、Ⅳ期诊断均正确，总准确率为82.5%。 结论 螺旋CT增强扫描对子宫内膜癌的诊断和分期均有价值。
目的 探讨子宫内膜癌中雌激素受体（ER）、孕激素受体（PR）和p53的表达及其临床意义。 方法 1994年1月-2009年11月，应用免疫组织化学Envision法检测52例子宫内膜癌中ER、PR和p53的表达情况并进行统计学分析。 结果 ER、PR和p53阳性表达率分别为51.9%、50.0%和46.2%。ER、PR的阳性表达率与癌组织的细胞分化程度有关（Plt;0.05）。随着组织学分级的增高，ER、PR阳性表达率逐渐降低（在Ⅰ、Ⅱ和Ⅲ级子宫内膜癌中，ER阳性表达率分别为64.0%、56.3%和18.2%， PR阳性表达率分别为72.0%、37.5%和18.2%）。随着组织学分级的增高及淋巴结转移，p53的阳性表达率逐渐增高（Plt;0.05），p53表达与ER、PR表达有关（Plt;0.05）。 结论 ER、PR和p53的表达与子宫内膜癌组织学分级和生物学行为密切相关，其测定对评估子宫内膜癌预后，指导临床治疗具有重要意义。
目的:总结分析子宫内膜癌临床特点、治疗方法的疗效及与各预后高危因素之间的关系，以提高临床诊疗水平。方法:回顾性分析我院1998年1月～2005年12月收治住院的子宫内膜癌患者499例的临床病理资料，总结患者的一般情况、临床特点并进行随访，分析内膜癌高危因素对预后的影响。采用寿命表法计算患者生存率，Wilcoxon (Gehan) 比分法及Cox比例风险模型分析预后因素。结果:(1) 手术－病理分期I、Ⅱ、Ⅲ期患者5年生存率分别为94%、100％、75.3％，IV期患者1年生存率57.1%、2年生存率11.4％。(2) 单因素分析显示：病理类型、手术－病理分期、组织学分级、肌层浸润深度、淋巴结转移和是否行淋巴结切除术是影响预后的高危因素。（3）多因素分析显示：病理类型、手术－病理分期、组织学分级和肌层浸润深度是影响患者预后的独立危险因素。结论:(1) 对具有高危因素的患者，如特殊病理类型、手术－病理分期期别晚、组织学分级为G3和深肌层浸润，应辅以术后治疗以提高生存率。(2)分期越晚，生存率越低（Plt;0.05）。